

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

GENEREX BIOTECHNOLOGY CORP

Form 8-K

August 14, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 1, 2002

Generex Biotechnology Corporation

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of Incorporation)	000-25169 ----- (Commission File Number)	82-049021 ----- (IRS Employer Identification No.)
--	---	--

33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 416/364-2551

(Former name or former address, if changed since last report)

Item 5. Other Events

Dr. Ivan Lieberburg has resigned as a director of the Company effective as of August 1, 2002. Dr. Lieberburg stated that due to the increasing demands of his position with Elan Corporation, he could no longer devote the time and attention necessary to serve as a director of the Company.

In January 2001, Generex established a joint venture with Elan International Services, Ltd. ("EIS") and Elan Corporation, plc ("Elan"). Pursuant to the Securities Purchase Agreement dated January 16, 2001, between Generex, Elan and EIS, EIS has the right to nominate one director to Generex's Board of Directors

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

for so long as EIS or its affiliates own at least 1.0% of the issued and outstanding shares of Common Stock. Dr. Lieberburg was the nominee of EIS thereunder. The Company has not been notified as to whether EIS will nominate a director to replace Dr. Lieberburg at this time.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENEREX BIOTECHNOLOGY CORPORATION

Dated: August 14, 2002

By: /s/ E. Mark Perri

E. Mark Perri, Chairman and CFO